Description: |
PNRI-299, was identified that selectively inhibited AP-1 transcription (IC(50) of 20 microM) without affecting NF-kappaB transcription (up to 200 microM) or thioredoxin (up to 200 microM). The molecular target of PNRI-299 was determined to be the oxidoreductase, redox effector factor-1 by an affinity chromatography approach. The selective redox effector factor-1 inhibitor, PNRI-299, significantly reduced airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model. These data validate AP-1 as an important therapeutic target in allergic airway inflammation. For the detailed information of PNRI-299, the solubility of PNRI-299 in water, the solubility of PNRI-299 in DMSO, the solubility of PNRI-299 in PBS buffer, the animal experiment (test) of PNRI-299, the cell expriment (test) of PNRI-299, the in vivo, in vitro and clinical trial test of PNRI-299, the EC50, IC50,and affinity,of PNRI-299, For the detailed information of PNRI-299, the solubility of PNRI-299 in water, the solubility of PNRI-299 in DMSO, the solubility of PNRI-299 in PBS buffer, the animal experiment (test) of PNRI-299, the cell expriment (test) of PNRI-299, the in vivo, in vitro and clinical trial test of PNRI-299, the EC50, IC50,and affinity,of PNRI-299, Please contact DC Chemicals. |